TAKE THIS POLL |
|
|
- Biota Holdings Limited (ASX:BTA) Quarterly Royalties from Relenza 24 Jul 2008 02:15 GMT
... and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection ...
- Impax sued over generic prostate drug 23 Jul 2008 18:27 GMT
... to regulators for a generic version of Flomax, used to treat benign prostatic hyperplasia. Boehringer Ingelheim Pharmaceuticals Inc. and Astellas Pharma Inc. sued Impax in U.S. district court in Northern ...
- Invitation to Q2 2008 Conference Call of MorphoSys AG On July 29, 2008 23 Jul 2008 15:28 GMT
... therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic ...
- MorphoSys Licenses RapMAT Technology To Astellas 23 Jul 2008 05:51 GMT
... therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic ...
- Astellas, Boehringer Ingelheim Sue to Protect Flomax 23 Jul 2008 02:13 GMT
... > Astellas, Boehringer Ingelheim Sue to Protect Flomax July 23, 2008 | Vol. 7 No. 143 Astellas, Boehringer ...
- Anika Therapeutics Reports 28% Increase in Revenue for Second Quarter 2008 22 Jul 2008 22:49 GMT
... by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS(TM) family of aesthetic dermatology products for facial wrinkles, scar remediation ...
- Roxane Recalls Hyperkalemia Drug Over Yeast Contamination 22 Jul 2008 21:31 GMT
... | Vol. 25 No. 14 Roxane Recalls Hyperkalemia Drug Over Yeast Contamination Roxane Laboratories, Boehringer Ingelheim's generic subsidiary, recalled two lots of sodium polystyrene sulfonate because one lot tested positive ...
- MM&M Awards 2008--and the finalists are: 22 Jul 2008 20:32 GMT
... & Mather and Allergan for Natrelle—The Natrelle Breast Implant Collection Ogilvy & Mather and Boehringer Ingelheim Pharmaceuticals for Mirapex— Print Ad StoneArch Creative and GN ReSound for GN ReSound Humor ...
- Boehringer seeks allies to tap local mart 22 Jul 2008 20:07 GMT
... Boehringer Ingelheim, the $17-billion German pharma major that set up a subsidiary in India three years ...
- MM&M Awards 2008 -- and the finalists are: 22 Jul 2008 18:33 GMT
... & Mather and Allergan for Natrelle—The Natrelle Breast Implant Collection Ogilvy & Mather and Boehringer Ingelheim Pharmaceuticals for Mirapex— Print Ad StoneArch Creative and GN ReSound for GN ReSound Humor ...
- Sparta Systems Demonstrates Continued Expansion in Global Life Science Markets 22 Jul 2008 15:50 GMT
... the deployment process. New European customers recently added to Sparta's growing base include: -- Boehringer Ingelheim: a top 20 global pharmaceutical company based in Germany and committed to the research, ...
- IMPAX Sued Based on ANDA for Generic Flomax(R) 22 Jul 2008 13:57 GMT
... IMPAX Sued Based on ANDA for Generic Flomax(R) IMPAX Laboratories, Inc. today announced Boehringer Ingelheim Pharmaceuticals Inc. ("Boehringer") and Astellas Pharma Inc. ("Astellas") have filed suit for patent infringement ...
- Argentina Pharmaceuticals and Healthcare Report Q3 2008: Competitive Intelligence on Argentina's Pharmaceuticals and Healthcare Industry 22 Jul 2008 10:30 GMT
... -- Roche -- Novartis -- GlaxoSmithKline (GSK) -- Sanofi-Aventis -- Merck & Co -- Boehringer Ingelheim -- Laboratorios Roemmers -- Laboratorios Bago For more information visit ...
- Drugs Designated As Orphan Drugs, Australia, July 2008 22 Jul 2008 09:16 GMT
... have lost at least 5% of their usual body weight Drug: nevirapine (VIRAMUNE) Sponsor: Boehringer Ingelheim Pty Limited Date of designation: 11 March 2003 Indication: for the prevention of mother ...
- Only 44.4 percent of Parkinson's disease patients receive drug treatment within one year of being diagnosed 22 Jul 2008 08:37 GMT
... with motor response complications). Fewer surveyed primary care physicians prescribe dopamine agonists, which include Boehringer Ingelheim's Mirapex, GlaxoSmithKline's Requip, generics (Ropinirole) and UCB/Schwarz Pharma's Neupro (Rotigotine), as a first-line therapy ...
- UPDATE 1-Astellas sues Impax over generic version of Flomax 22 Jul 2008 08:14 GMT
... a generic version of the Japanese drug maker's prostate drug Flomax. Astellas and Germany's Boehringer Ingelheim Pharmaceuticals Inc, which co-promotes Flomax in the United States, jointly filed the suit at ...
- Astellas sues Impax over generic version of Flomax 22 Jul 2008 07:31 GMT
... for a generic version of Japanese drug maker's prostate drug Flomax. Astellas and Germany's Boehringer Ingelheim Pharmaceuticals Inc, which co-promotes Flomax in the United States, jointly filed the suit at ...
- Producing purified plasmid DNA 22 Jul 2008 05:33 GMT
... a technology and sales collaboration late last month. The collaboration includes a transfer of Boehringer Ingelheim technology to GENEART for the production and purification of plasmid DNA. The two companies ...
- Global Thought Leaders Outline Unmet Needs, Opportunities in Anxiety and Depression Market in New Me 21 Jul 2008 20:13 GMT
... CRH and more. Companies/Partnerships discussed include: Abbott, AstraZeneca, Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly, Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono, Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca, Wyeth, and others. This report can ...
- Global Thought Leaders Outline Unmet Needs, Opportunities in Anxiety and Depression Market in New MedPredict Report 21 Jul 2008 19:56 GMT
... CRH and more. Companies/Partnerships discussed include: Abbott, AstraZeneca, Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly, Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono, Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca, Wyeth, and others. This report can ...
- Biota and GSK Conclude Litigation Through Mediation 21 Jul 2008 15:57 GMT
... and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection ...
- --> Biota and GSK Conclude Litigation Through Mediation 21 Jul 2008 14:19 GMT
... and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection ...
- Biota and GSK Conclude Litigation Through Mediation 21 Jul 2008 14:05 GMT
... and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection ...
- Gilead Sciences: Industry Landscape, Strong Growth Make It a Buy 20 Jul 2008 20:50 GMT
... Gilead’s Truvada. Other major players in HIV market include GSK, Bristol Meyers, Abbott, Roche, Boehringer Ingelheim, Pfizer, Merck, Barr and Kohl Medical. Yet the advent of Gilead’s Truvada and later ...
1 - 25 of 85 next >
News by PR Newswire
|
